To assess the independent prognostic value of CSMD1 gene expression in adjuvant treated TNBC patients, we performed multivariable Cox regression analysis adjusting for tumor size (≤ 20 mm, > 20 mm), tumor grade (2, 3), and lymph node status (N0, N +) using OS and IDFS as the clinical endpoints. The gene discussed is CSMD1; the disease is neoplasm.